CTIS2023-510227-30-00进行中（未招募）1 期
Phase II Randomized Clinical Trial of quinacrine versus metronidazole in resistant giardiasis in children: Quin4Kids - QUIN4KIDS
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz0 个研究点目标入组 48 人开始时间: 2024年2月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Children aged 1 to 18 years of age., Diagnosed with intestinal giardiasis., Informed consent/assent., Refractory to first line treatment
排除标准
- •History of allergy or previous positive skin-test reaction to any of the drug compounds included., Liver disease and/or liver enzymes > x3., Pregnant woman., Oral intolerance.
研究者
相似试验
尚未招募
2 期
Clinical trial of Methotrexate associated to Hydroxyurea versus placebo and Hydroxyurea in patients with sickle cell diseaseRBR-57qbjvCentro Infantil Boldrini
已完成
2 期
Randomized Controlled Phase 2 Clinical Trial of JPH203 in Patients With Advanced Biliary Tract Cancers.Advanced Biliary Tract CancersJPRN-UMIN000034080J-Pharma Co., Ltd.106
进行中（未招募）
1 期
A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer.ocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-ESPuma Biotechnology Inc.126
进行中（未招募）
1 期
A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer.ocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-PTPuma Biotechnology Inc.126
进行中（未招募）
1 期
A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer. - NSABP FB-7 STUDYocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-ITPuma Biotechnology Inc.141